Warrant Exercise Price Halved to $2.50 Post-Split, Increasing Dilution Risk
SBFM sits 15% above its 52-week low of $2.11 on light trading volume (0.1× avg).
Summary
Sunshine Biopharma's definitive filing reveals a 50% reduction in Series C Warrant exercise price to $2.50 post-reverse split, making them nearly exercisable and increasing future dilution.
Key Events · Financing and Capital Events · SBFM
-
Warrant Exercise Price Reduced
The exercise price of Series C Warrants will be reduced from $5.00 to $2.50 per share, effective 20 days after the mailing of this statement, due to a provision triggered by the 1-for-10 reverse stock split.
-
Increased Dilution Potential
The 50% reduction in the warrant exercise price, bringing it close to the current stock price of $2.43, significantly increases the likelihood of warrant exercise and subsequent dilution for existing shareholders.
-
Shareholder Approval Confirmed
The company's CEO, Dr. Steve N. Slilaty, holding 86.0% of voting power, approved the warrant stockholder approval provisions by written consent on May 28, 2026.
-
Follows Recent Dilutive Offering
This adjustment relates to Series C Warrants issued in a $6.0 million public offering that closed on May 19, 2026, which was already noted for its highly dilutive nature.
Analysis · SBFM · Life Sciences
This definitive information statement confirms shareholder approval for warrant provisions, crucially detailing that the Series C Warrants' exercise price will be reduced from $5.00 to $2.50 following the recent 1-for-10 reverse stock split. This 50% reduction, effective 20 days after mailing, makes the warrants nearly at-the-money with the current stock price of $2.43, significantly increasing the likelihood of exercise and future dilution for existing shareholders. This comes after a highly dilutive $6 million offering and worsening financial health.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.6% of the 317 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SBFM was trading at $2.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $2.11 to $24.30. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.